Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells-Reference-Cited by-同舟云学术

Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells

Published:1998-08 Issue:34 Volume:273 Page:22128-22135
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Giraudo Enrico,Primo Luca,Audero Enrica,Gerber Hans-Peter,Koolwijk Pieter,Soker Shay,Klagsbrun Michael,Ferrara Napoleone,Bussolino Federico

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference59 articles.

1. Molecular mechanisms of blood vessel formation

2. Angiogenesis in cancer, vascular, rheumatoid and other disease

3. Mechanisms of angiogenesis

4. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

5. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Cited by 228 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrospun polyhedral oligomeric silsequioxane-poly(carbonate-urea) urethane for fabrication of hemocompatible small-diameter vascular grafts with angiogenesis capacity;International Journal of Biological Macromolecules;2024-10

2. In vitro analysis of VEGF-mediated endothelial permeability and the potential therapeutic role of Anti-VEGF in severe dengue;Biochemistry and Biophysics Reports;2024-09

3. The crosstalk between neuropilin-1 and tumor necrosis factor-α in endothelial cells;Frontiers in Cell and Developmental Biology;2024-06-27

4. Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors;Journal of Molecular Structure;2024-06

5. Development of Biotinylated Liposomes Encapsulating Metformin for Therapeutic Targeting of Inflammation-Based Diseases;Pharmaceutics;2024-02-05